Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 55 % of short-term debt in 2026; threshold 65 %.
-
Busy address KBO
50 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2026
Asahi Kasei Bioprocess Europe from Schaarbeek, company number BE0480190679, closed financial year 2026 with a result of € 8.7 million after tax. For that financial year Asahi Kasei Bioprocess Europe recorded revenue of € 136.2 million and equity of € 9.3 million. Compared with financial year 2025, the result moved from € 6 million to € 8.7 million. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 12, 2026.
€ 9.3 million
▲ 23% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 8.7 million
▲ 46% vs 2025
Profit after tax over the fiscal year.
€ 15.2 million
▲ 16% vs 2025
Cash and bank balances on the last day of the fiscal year.
€ 7 million paid out
80 % of the profit went to the shareholders, mostly to Asahi Kasei Life Science Corporation (100 % of the shares). That is where the money ends up.
People and assets in 2026
16.8
▼ 0.1 vs 2025
Average over the fiscal year, from the social balance sheet.
€ 4.2 million
▲ 5% vs 2025
€ 250,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 464,057
▼ 16% vs 2025
Book value of vehicles, furniture and equipment.
Debts at end 2026
None
No bank loans on the last day of the fiscal year.
€ 58.4 million
▲ 9% vs 2025
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 177 days on average.
€ 976,143
▲ 22% vs 2025
Taxes, VAT and social contributions still to pay.
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Revenue | € 135,659,221 | € 121,958,665 | € 125,565,322 | € 136,188,970 | ▲ 8% |
| Profit after taxes | € 8,351,028 | € 4,971,074 | € 5,978,520 | € 8,743,367 | ▲ 46% |
| Equity | € 16,604,815 | € 13,575,888 | € 7,554,408 | € 9,297,775 | ▲ 23% |
| Total debts | € 77,652,957 | € 60,170,979 | € 66,342,554 | € 66,388,242 | |
| Cash | € 28,507,099 | € 9,317,616 | € 13,122,343 | € 15,241,700 | ▲ 16% |
| Retained profit | € 16,104,815 | € 13,075,888 | € 7,054,408 | € 8,797,775 | ▲ 25% |
| Dividend | € 0 | € 8,000,000 | € 12,000,000 | € 7,000,000 | ▼ 42% |
| Balance sheet total | € 94,270,012 | € 73,746,868 | € 73,950,982 | € 75,686,017 | ▲ 2% |
| Employees (FTE) | 16 | 16.3 | 16.9 | 16.8 | ▼ 0.1 |
By revenue, Asahi Kasei Bioprocess Europe ranks 1st of 4 companies with main activity “Markt- en opinieonderzoek” in Schaarbeek that publish figures (fiscal year 2026).
Key figures of Asahi Kasei Bioprocess Europe, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
Ask about Asahi Kasei Bioprocess Europe the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Asahi Kasei Bioprocess Europe?
What happened at Asahi Kasei Bioprocess Europe in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Yutaka Yoshimoto stepped down as director. NBB
- Atsuo Kubota stepped down as director. NBB
- New annual accounts for financial year 2026: profit of € 8.7 million (▲ 46% vs 2025). Source: NBB ↗
- Yutaka Yoshimoto became a director. NBB
- Yusuke Kanazawa stepped down as director. NBB
- Masahi Yamamoto stepped down as director. NBB
- Atsuo Kubota became a director. NBB
- Yusuke Kanazawa became a director. NBB
In short
From € 8.4 million profit in 2023 to € 8.7 million profit in 2026.
Paid € 9.7 million in corporate taxes since 2023.
Best year ever: 2026, with € 8.7 million profit.
Paid out € 27 million in dividends to the owners in total.
Management
The shares are held by Asahi Kasei Life Science Corporation (100%).
Directors
According to the 2026 annual accounts
Yutaka Yoshimoto
Director
since 2026 · until 2032
Yusuke Kanazawa
Director
since 2023 · until 2026
Atsuo Kubota
Director
since 2024 · until 2030
Masahi Yamamoto
Director
since 2021 · until 2026
Shareholders
Asahi Kasei Life Science Corporation
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Auguste Reyerslaan 70
1030 Schaarbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 50 companies are registered at this address.
All companies at this address →Openbaar Centrum voor Maatschappelijk Welzijn van Schaarbeek
Belgische federatie van de chemische industrie en van life sciences
€ 3.8 million revenue · 2025
Industrie van Vernissen, Stopverven, Drukinkten en Verven voor de Schone Kunst
€ 24,385 gross margin · 2025
FEDERATION INTERNATIONALE Du LAIT
€ 710,637 gross margin · 2025
BIOPLUS-PROBOIS
+45 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Schaarbeek
Same main activity (Markt- en opinieonderzoek), 30 active companies in Schaarbeek, largest first.
Centre d'Information sur les Media
€ 12.9 million revenue · 2025
€ 772,666 gross margin · 2025
€ 589,444 gross margin · 2024
€ 573,293 gross margin · 2025
ASSOCIATION POUR UNE FONDATION TRAVAIL-UNIVERSITE
€ 521,943 gross margin · 2025
THE EUROPEAN MULTIPLE SCLEROSIS PLATFORM
€ 456,794 gross margin · 2025
Details
- Company number
- 0480.190.679
- VAT number
- BE 0480.190.679
- Registered office
- Auguste Reyerslaan 70, 1030 Schaarbeek
- Names & denominations
- Asahi Kasei Bioprocess Europe
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 9 May 2003
- Peppol
- Active · Active since 29 Nov 2025
- Activities · NACE
Markt- en opinieonderzoek
Marktonderzoekbureaus
Groothandel in farmaceutische en medische artikelen
Overige technische testen en toetsen
Overige detailhandel in nieuwe artikelen neg
Overige gespecialiseerde detailhandel in artikelen, andere dan voedingsmiddelen, n.e.g.
Technische testen en analyses